Key facts
- CancerIQ’s last known valuation is $50.0M (Mar 2022).
- It has raised $30.8M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Matter (Consulting Services (B2B)), Lightbank (Venture Capital), MSD Global Health Innovation Fund, HealthX Ventures, Impact Engine — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for CancerIQ
- ·The full record, as it builds
Funding rounds
No funding rounds for CancerIQ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CancerIQ
Developer of a precision health technology designed for doctors to identify and manage patients at high risk for cancer. The company's platform offers predictive analytics and screening tools to identify at-risk patients, clinical guidance with proven outcomes, a digital genetic test ordering platform, and patient management and education tools, enabling clinicians to save time, reduce the cost of care, and improve outcomes by detecting cancer at an early stage.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2013
- Employees
- 34
- Website
- canceriq.com/
- Ownership
- Privately Held (backing)
CancerIQ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CancerIQ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CancerIQ in its N-PORT filings yet. We sweep new filings monthly.